Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 109

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 109
---
 and results of operations could be materially harmed. In addition, our success depends on demand for our products. Our customers may experience volatility in their genetic testing demand in the ordinary course of their operations. Since our tests are often purchased on a test -by -testbasis rather than pursuant to long -termpurchasing arrangements, our consumer base may fluctuate or decrease. In addition, the long -termdistribution agreements that we do have may be terminated, which could affect demand as well. The loss of any of our customers, or a reduction in orders or difficulties collecting payments for tests, could significantly reduce our revenue and adversely affect our business, results of operations, financial condition and growth prospects. We may be forced to make significant changes to our anticipated pricing, sales and revenue model as well to compete with our competitors, and there is no guarantee that such changes, if implemented, will be successful. Our industry is subject to rapidly changing technology, including the introduction of artificial intelligence, and new scientific data, and our failure to keep pace with such changes could render us obsolete and harm our operating results and business. Our industry is characterized by rapid technological change, including the increasing presence of artificial intelligence, increasingly larger amounts of data, frequent new testing services, and evolving industry standards. Our success depends on our ability to keep pace with these technologies and the evolving needs of our customers on a timely and cost -effectivebasis and to pursue new market opportunities that develop as a result of technological and scientific advances. We must continually update our offerings to reflect new scientific knowledge about genes and genetic variations and their role in diseases and treatment therapies, or else our tests could become obsolete or not cost -effectiveand our business adversely affected. In addition, our entry into the pharmacogenetic testing markets expose us to increased liability. Errors or mistakes in interpreting test results could have a significant adverse impact on our business, results of operations, financial condition and growth prospects, as we may be subject to liability for errors, misunderstandings, or inappropriate reliance on information we provide to clinicians, geneticists or patients. We maintain liability insurance, but this may not fully protect us from financial impact, injury to our reputation, or suspension of sales of our tests. The sizes of the markets and forecasts of market growth for the demand of our products and services, including our research services and other key potential success factors are based on a number of complex assumptions and estimates, and may ultimately be inaccurate. We estimate annual total addressable markets and forecasts of market growth for our services. We have also developed a